Stevanato Group SpA (STVN) Noticias

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Stevanato Group to Present at Upcoming Investor Conferences

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Stevanato Group Reports Financial Results for the Third Quarter of 2024

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the...

Stevanato Group to Report Third Quarter 2024 Financial Results on November 5, 2024

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical...

Stevanato Group Will Introduce Its Large-Volume Vertiva® 10mL On-Body Delivery System Platform for Injectable Therapies at CPHI Milan

The platform provides a versatile pre-filled and pre-loaded on-body solution, suitable for highly viscous...

Stevanato Group, Gerresheimer and SCHOTT Pharma, Announce Strategic Industry “Alliance for RTU”

Market advances adoption of ready-to-use containers Improved operational efficiency in pharmaceutical...

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Stevanato Group to Present at Upcoming Investor Conferences

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]